{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:20:58Z","timestamp":1774282858526,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s12325-014-0102-3","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T17:10:59Z","timestamp":1392657059000},"page":"345-361","source":"Crossref","is-referenced-by-count":32,"title":["Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Takashi","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fukatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshishige","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"102_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 5th edn. 2011\/2012 update. Available from: http:\/\/www.idf.org\/diabetesatlas\/ . Accessed 19 Nov 2013."},{"key":"102_CR2","unstructured":"Ministry of Health, Labour and Welfare. Summary of Patient Survey 2008. Available from: http:\/\/www.mhlw.go.jp\/english\/database\/db-hss\/sps_2008.html . Accessed 19 Nov 2013"},{"key":"102_CR3","unstructured":"National Institute of Health and Nutrition. Outline of the National Health and Nutrition Survey Japan, 2007. Available from: http:\/\/www0.nih.go.jp\/eiken\/english\/research\/project_nhns.html\/ . Accessed 19 Nov 2013."},{"key":"102_CR4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jdi.12044","volume":"4","author":"S Fukushima","year":"2013","unstructured":"Fukushima S, Nakagami T, Suto C, Hirose A, Uchigata Y. Prevalence of retinopathy and its risk factors in a Japanese population. J Diabetes Investig. 2013;4:349\u201354.","journal-title":"J Diabetes Investig"},{"key":"102_CR5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.2040-1124.2010.00019.x","volume":"1","author":"N Hotta","year":"2010","unstructured":"Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: a questionnaire survey of 18385 diabetics over a 10-year period. J Diabetes Investig. 2010;1:66\u201376.","journal-title":"J Diabetes Investig"},{"key":"102_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jdi.12042","volume":"4","author":"AI Vinik","year":"2013","unstructured":"Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4\u201318.","journal-title":"J Diabetes Investig"},{"key":"102_CR7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"102_CR8","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"102_CR9","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"102_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","volume":"28","author":"Y Ohkubo","year":"1995","unstructured":"Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103\u201317.","journal-title":"Diabetes Res Clin Pract"},{"key":"102_CR11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.2040-1124.2010.00004.x","volume":"1","author":"MA Nauck","year":"2010","unstructured":"Nauck MA, Vardarli I. Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig. 2010;1:24\u201336.","journal-title":"J Diabetes Investig"},{"key":"102_CR12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u201312.","journal-title":"JAMA"},{"key":"102_CR13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","volume":"31","author":"TJ Hoerger","year":"2008","unstructured":"Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81\u20136.","journal-title":"Diabetes Care"},{"key":"102_CR14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"key":"102_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261:32\u201343.","journal-title":"J Intern Med"},{"key":"102_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na\u00a0+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Investig. 1994;93:397\u2013404.","journal-title":"J Clin Investig"},{"key":"102_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"102_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.2040-1124.2012.00227.x","volume":"3","author":"N Harada","year":"2012","unstructured":"Harada N, Inagaki N. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig. 2012;3:352\u20133.","journal-title":"J Diabetes Investig"},{"key":"102_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","volume":"139","author":"E Kurosaki","year":"2013","unstructured":"Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013;139:51\u20139.","journal-title":"Pharmacol Ther"},{"key":"102_CR20","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723\u20139.","journal-title":"Diabetes"},{"key":"102_CR21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo controlled, phase 3 trial. Diabetes Care. 2010;33:2217\u201324.","journal-title":"Diabetes Care"},{"key":"102_CR22","unstructured":"Dapagliflozin (Forxiga): EU summary of product characteristics. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/27188\/SPC\/Forxiga+5%20mg++%26+10+mg+film+coated+tablets\/ . Accessed 19 Nov 2013."},{"key":"102_CR23","unstructured":"Canagliflozin (Invokana): prescribing information. Available from: http:\/\/www.invokanahcp.com\/prescribing-information.pdf\/ . Accessed 19 Nov 2013."},{"issue":"1","key":"102_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2011.01340.x","volume":"164","author":"K Yamamoto","year":"2011","unstructured":"Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol. 2011;164(1):181\u201391.","journal-title":"Br J Pharmacol"},{"key":"102_CR25","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","volume":"53","author":"H Kakinuma","year":"2010","unstructured":"Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010;53:3247\u201361.","journal-title":"J Med Chem"},{"key":"102_CR26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"102_CR27","unstructured":"English translation of Attachment 1 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012. Guideline for Bioequivalence Studies of Generic Products. Available from: http:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/Generic\/GL-E_120229_BE.pdf . Accessed 28 Jan 2014."},{"key":"102_CR28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1185\/03007995.2012.689956","volume":"28","author":"LE Nicolle","year":"2012","unstructured":"Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167\u201371.","journal-title":"Curr Med Res Opin"},{"key":"102_CR29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","volume":"28","author":"P Nyirjesy","year":"2012","unstructured":"Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173\u20138.","journal-title":"Curr Med Res Opin"},{"key":"102_CR30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650\u20137.","journal-title":"Diabetes Care"},{"key":"102_CR31","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"JP Wilding","year":"2009","unstructured":"Wilding JP, Norwood P, T\u2019joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656\u201362.","journal-title":"Diabetes Care"},{"key":"102_CR32","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223\u201333.","journal-title":"Lancet"},{"key":"102_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:473\u20138.","journal-title":"J Diabetes Complicat"},{"key":"102_CR34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:479\u201384.","journal-title":"J Diabetes Complicat"},{"key":"102_CR35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357\u201365.","journal-title":"Diabetes Obes Metab"},{"key":"102_CR36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669\u201372.","journal-title":"Diabetes Obes Metab"},{"key":"102_CR37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","volume":"28","author":"A Sarashina","year":"2013","unstructured":"Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"102_CR38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13340-011-0037-8","volume":"2","author":"T Kadokura","year":"2011","unstructured":"Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2:172\u201382.","journal-title":"Diabetol Int"},{"key":"102_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ajcn\/60.1.29","volume":"60","author":"MG Carlson","year":"1994","unstructured":"Carlson MG, Snead WL, Campbell PJ. Fuel and energy metabolism in fasting humans. Am J Clin Nutr. 1994;60:29\u201336.","journal-title":"Am J Clin Nutr"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0102-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T18:09:42Z","timestamp":1565201382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0102-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,18]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0102-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,18]]}}}